Context TherapeuticsCNTX
CNTX
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
24% more funds holding
Funds holding: 42 [Q3] → 52 (+10) [Q4]
21.47% more ownership
Funds ownership: 75.58% [Q3] → 97.05% (+21.47%) [Q4]
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
31% less capital invested
Capital invested by funds: $111M [Q3] → $76.4M (-$34.7M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
418%
upside
Avg. target
$6
677%
upside
High target
$9
1,066%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 157 met price target | 548%upside $5 | Buy Reiterated | 21 Mar 2025 |
D. Boral Capital Jason Kolbert 31% 1-year accuracy 92 / 297 met price target | 1,066%upside $9 | Buy Maintained | 21 Mar 2025 |
JMP Securities Silvan Tuerkcan 31% 1-year accuracy 17 / 54 met price target | 418%upside $4 | Market Outperform Initiated | 8 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, “We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a strengthened financial position, and enhancements to our leadership team, all aligning with our mission to develop innovative T cell-engaging bispecific antibodies for solid tumors.
Neutral
GlobeNewsWire
3 weeks ago
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 46,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences:
Neutral
GlobeNewsWire
2 months ago
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The Phase 1 dose escalation and expansion trial is enrolling patients with CLDN6-positive gynecologic and testicular cancers.
Neutral
GlobeNewsWire
2 months ago
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025. “I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully integrated global biopharmaceutical companies to help Context continue to deliver on the promise of T cell engagers for solid tumors,” said Andy Pasternak.
Neutral
GlobeNewsWire
4 months ago
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody
Neutral
GlobeNewsWire
4 months ago
Context Therapeutics to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November:
Neutral
GlobeNewsWire
5 months ago
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Neutral
GlobeNewsWire
5 months ago
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.
Negative
Zacks Investment Research
6 months ago
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Charts implemented using Lightweight Charts™